Skip to main content

Biotech

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Fore Sight

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
Isabella Ward
OpenAI and Anthropic Sign Letter to Prevent AI-Developed Biological Weapons
Bioweapons

OpenAI and Anthropic Sign Letter to Prevent AI-Developed Biological Weapons

Emily Mullin
A New Hantavirus Vaccine Is in the Works
Public Health

A New Hantavirus Vaccine Is in the Works

Javier Carbajal